Topics

Ebola

Novavax's Ebola vaccine shows human immune response

Novavax's Ebola vaccine shows human immune response

Novavax Inc.'s Ebola vaccine helped healthy people develop an immune response against the deadly virus in an early trial. In a randomized study compared against a placebo, the vaccine pushed participants' immune systems to build up antibodies to fight Ebola when combined with a supplement to boost production of the proteins, according to Greg Glenn, Novavax's head of research. "We have a very, very robust immune response," Glenn said by phone. Monkeys who exhibited the same response to the vaccine "were completely protected" from Ebola. Novavax presented a study about the effect of the vaccine on primates in March. Ebola ravaged West Africa...

Loading

70°